4DMedical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FDMDF research report →
Price Chart
About the company
4DMedical Limited operates as a medical technology firm with operations spanning both Australia and the United States. A core aspect of its business involves the commercialization of XV Technology, an advanced four-dimensional system for lung imaging. The company's offerings further extend to a software-as-a-service (SaaS) delivery model, alongside its proprietary XV lung ventilation analysis software.
- CEO
- Andreas Fouras
- IPO
- 2021
- Employees
- 124
- HQ
- Carlton, VIC, AU
Get TickerSpark's AI analysis on FDMDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.77B
- P/E
- -12.06
- Fwd P/E
- 1691.11
- PEG
- 0.01
- P/S
- 539.93
- P/B
- -68.06
- EV/EBITDA
- -64.52
- Div Yield
- 0.00%
- Gross Margin
- -396.61%
- Op Margin
- -1166.28%
- Net Margin
- -3684.62%
- ROE
- -890.76%
- ROIC
- -37.27%
Latest fiscal year · YoY change
- Revenue
- $5.85M+91.9%
- Gross Profit
- $5.39M+91.6%
- Op Income
- $-29,220,394
- Net Income
- $-30,069,854+16.4%
- EPS
- $-0.07+35.5%
- OCF Growth
- -11.7%
- FCF Growth
- -10.9%
- 52W High
- $5.00
- 52W Low
- $0.29
- 50D MA
- $2.73
- 200D MA
- $2.58
- Beta
- 1.97
- RSI (14)
- 58
- Avg Volume
- 899
No earnings-call transcripts are available for FDMDF yet.
- Free Float
- 73.8%
- Shares Outstanding
- 599.64M
- Float Shares
- 442.72M
Our FDMDF coverage
Recent articles, reports, and earnings notes.
No research on FDMDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FDMDF report →4DMedical Limited (FDMDF) M&A Call Transcript
seekingalpha.com · Jun 9
4DMedical Limited (FDMDF) Discusses Clinical Use of CT:VQ in Patient Selection for Lung Volume Reduction Surgery Transcript
seekingalpha.com · May 21
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
prnewswire.com · Mar 30
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
prnewswire.com · Jan 26
4DMedical Limited (FDMDF) Discusses Imaging Technology Portfolio and Market Positioning in Cardio-Pulmonary Diagnostics Transcript
seekingalpha.com · Jan 18
4DMedical Limited (FDMDF) Discusses Expansion of Distribution Agreement for CT:VQ Non-Contrast Lung Imaging Solution Transcript
seekingalpha.com · Dec 3
4DMedical Limited - Special Call
seekingalpha.com · Sep 17
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
prnewswire.com · Sep 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.